Market capitalization | $45.95m |
Enterprise Value | $143.36m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 17.70 |
P/S ratio (TTM) P/S ratio | 5.67 |
P/B ratio (TTM) P/B ratio | 3.97 |
Revenue growth (TTM) Revenue growth | 184.93% |
Revenue (TTM) Revenue | $8.10m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
2 Analysts have issued a Omega Therapeutics Inc forecast:
2 Analysts have issued a Omega Therapeutics Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 8.10 8.10 |
185%
185%
|
|
Gross Profit | 0.79 0.79 |
123%
123%
|
|
EBITDA | -67 -67 |
36%
36%
|
EBIT (Operating Income) EBIT | -74 -74 |
33%
33%
|
Net Profit | -73 -73 |
32%
32%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Omega Therapeutics, Inc. engages in the development of DNA-sequence-targeting, mRNA-encoded therapeutics. It offers its product under the OMEGA platform. The company was founded by Noubar B. Afeyan and David Berry on July 13, 2016 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Kaan Certel |
Employees | 94 |
Founded | 2016 |
Website | www.omegatherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.